Subscribe
shutterstock_2169738405_t_schneider
T. Schneider / Shutterstock.com
5 July 2022Big PharmaMuireann Bolger

Irish pharma company prevails in US pay-for-delay case

The ruling marks the latest development of a long-running dispute over the alleged delay of a generic version of the blockbuster painkiller.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Generic maker pays $145m to settle antitrust suit
21 July 2022   California company resolves pay-for-delay issue over opioids | Allegations were brought by direct purchasers eight years ago.
Americas
FTC hits Amneal, Impax and Endo with antitrust suit
28 January 2021   The US Federal Trade Commission is suing Endo Pharmaceuticals, Impax Laboratories, and Impax’s owner Amneal Pharmaceuticals, alleging that they were party to a 2017 agreement that violated antitrust law.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Americas
Generic maker pays $145m to settle antitrust suit
21 July 2022   California company resolves pay-for-delay issue over opioids | Allegations were brought by direct purchasers eight years ago.
Americas
FTC hits Amneal, Impax and Endo with antitrust suit
28 January 2021   The US Federal Trade Commission is suing Endo Pharmaceuticals, Impax Laboratories, and Impax’s owner Amneal Pharmaceuticals, alleging that they were party to a 2017 agreement that violated antitrust law.

More on this story

Americas
Generic maker pays $145m to settle antitrust suit
21 July 2022   California company resolves pay-for-delay issue over opioids | Allegations were brought by direct purchasers eight years ago.
Americas
FTC hits Amneal, Impax and Endo with antitrust suit
28 January 2021   The US Federal Trade Commission is suing Endo Pharmaceuticals, Impax Laboratories, and Impax’s owner Amneal Pharmaceuticals, alleging that they were party to a 2017 agreement that violated antitrust law.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims